

# Pulmonary Arterial Hypertension Panel, Sequencing and Deletion/Duplication

Pulmonary arterial hypertension (PAH) is caused by widespread occlusion or destruction of the smallest pulmonary arteries, leading to increased blood flow resistance, right ventricular hypertrophy, and heart failure. Genetic testing is most appropriate when no obvious etiology for pulmonary hypertension is found or if a family history of PAH exists.

## Disease Overview

### Symptoms

- Shortness of breath
- Fatigue
- Syncope
- Chest pain
- Palpitations
- Edema

### Genetics

#### Genes

See [Genes Tested](#) table for genes included in the panel.

### Epidemiology

Incidence:1-2/million

Approximately 80% of PAH is idiopathic and 20% is heritable.

### Inheritance

- Autosomal dominant: *ACVRL1*, *BMPR2*, *CAV1*, *ENG*, *GDF2*, *KCNA5*, *KCNK3*, and *SMAD9*
- Autosomal recessive: *EIF2AK4*, *TBX4*

## Test Interpretation

### Methodology

This test is performed using the following sequence of steps:

- Selected genomic regions, primarily coding exons and exon-intron boundaries, from the targeted genes are isolated from extracted genomic DNA using a probe-based hybrid capture enrichment workflow.
- Enriched DNA is sequenced by massively parallel sequencing (MPS; also known as next generation sequencing [NGS]) followed by paired-end read alignment and variant calling using a custom bioinformatics pipeline.
- Sanger sequencing is performed as necessary to fill in regions of low coverage and in certain situations, to confirm variant calls.
- The pipeline includes an algorithm for detection of large (single exon-level or larger) deletions and duplications.
- Large deletion/duplication calls made using MPS are confirmed by an orthogonal exon-level microarray when sample quality and technical conditions allow.

### Clinical Sensitivity

- 75-80% for familial cases<sup>1,2</sup>
- ~25% for simplex cases<sup>1,2</sup>

## Tests to Consider

### [Pulmonary Arterial Hypertension \(PAH\) Panel, Sequencing and Deletion/Duplication 2009345](#)

**Method:** Massively Parallel Sequencing

Preferred test to confirm a diagnosis of PAH, especially in those with a family history of PAH

### [Familial Targeted Sequencing 3005867](#)

**Method:** Massively Parallel Sequencing

- Testing for a known familial sequence variant by sequencing gene of interest. A copy of the family member's test result documenting the familial gene variant is REQUIRED.
- To determine if the variant(s) of interest are detectable by this assay, contact an ARUP genetic counselor at 800-242-2787.

## Analytic Sensitivity

For massively parallel sequencing:

Variant Class	Analytic Sensitivity (PPA) Estimate <sup>a</sup> (%) and 95% Credibility Region (%)	Analytic Specificity (NPA) (%)
SNVs	>99 (96.9-99.4)	>99.9
Deletions 1-10 bp <sup>b</sup>	93.8 (84.3-98.2)	>99.9
Insertions 1-10 bp <sup>b</sup>	94.8 (86.8-98.5)	>99.9
Exon-level <sup>c</sup> deletions	97.8 (90.3-99.8) [2 exons or larger] 62.5 (38.3-82.6) [single exon]	>99.9
Exon-level <sup>c</sup> duplications	83.3 (56.4-96.4) [3 exons or larger]	>99.9

<sup>a</sup>Genes included on this test are a subset of a larger methods-based validation from which the PPA values are derived. These values do not apply to testing performed by multiplex ligation-dependent probe amplification (MLPA).

<sup>b</sup>Variants greater than 10 bp may be detected, but the analytic sensitivity may be reduced.

<sup>c</sup>In most cases, a single exon deletion or duplication is less than 450 bp and 3 exons span a genomic region larger than 700 bp.

bp, base pairs; NPA, negative percent agreement; PPA, positive percent agreement; SNVs, single nucleotide variants

## Limitations

- A negative result does not exclude a heritable form of pulmonary arterial hypertension.
- Diagnostic errors can occur due to rare sequence variations.
- Interpretation of this test result may be impacted if the individual has had an allogeneic stem cell transplantation.
- The following will not be evaluated:
  - Variants outside the coding regions and intron-exon boundaries of the targeted genes (excluding the 5' untranslated region of *ENG*, and a region of *ACVRL1* intron 9 encompassing the CT-rich variant hotspot region)
  - Regulatory region variants and deep intronic variants
  - Breakpoints of large deletions/duplications
- The following may not be detected:
  - Deletions/duplications/insertions of any size by massively parallel sequencing
  - Large duplications less than 3 exons in size
  - Single exon deletions/duplications in the following exons:
    - *ENG* (NM\_001114753) 1
  - Noncoding transcripts
  - Some variants due to technical limitations in the presence of pseudogenes, repetitive, or homologous regions
  - Low-level somatic variants

## Genes Tested

Gene	MIM Number	Disorder	PAH Attributable to Gene
<i>ACVRL1</i>	601284	HHT type 2	1%
<i>BMPR2</i>	600799	<i>BMPR2</i> -related PAH; PAH1; PVOD type 1	~75% of familial cases; ~25% of simplex cases
<i>CAV1</i>	601047	PAH3	~1%
<i>EIF2AK4</i>	609280	PVOD2	>10%
<i>ENG</i>	131195	HHT type 1	~1%
<i>GDF2</i>	615506	HHT type 5	Unknown

HHT, hereditary hemorrhagic telangiectasia; ICPPS, Ischiocoxopodopatellar syndrome; PAH, pulmonary arterial hypertension; PAPPAS, posterior amelia with pelvic and pulmonary hypoplasia syndrome; PCH, pulmonary capillary hemangiomas; PVOD, pulmonary veno-occlusive disease

Gene	MIM Number	Disorder	PAH Attributable to Gene
<i>KCNA5</i>	176267	Familial atrial fibrillation 7	Unknown
<i>KCNK3</i>	603220	PAH4	~1-3%
<i>SMAD9</i>	603295	PAH2	Unknown
<i>TBX4</i>	147891; 601360	ICPPS; PAPPAS	Unknown

HHT, hereditary hemorrhagic telangiectasia; ICPPS, Ischiocoxopodopatellar syndrome; PAH, pulmonary arterial hypertension; PAPPAS, posterior amelia with pelvic and pulmonary hypoplasia syndrome; PCH, pulmonary capillary hemangiomatosis; PVOD, pulmonary veno-occlusive disease

## References

1. Austin ED, Loyd JE. [The genetics of pulmonary arterial hypertension](#). *Circ Res*. 2014;115(1):189-202.
2. Garcia-Rivas G, Jerjes-Sánchez C, Rodriguez D, et al. [A systematic review of genetic mutations in pulmonary arterial hypertension](#). *BMC Med Genet*. 2017;18(1):82.

## Additional Resources

Austin ED, Loyd JE, Phillips JA III. [Heritable pulmonary arterial hypertension](#). In: Adam MP, Ardinger HH, Pagon RA, et al, editors. GeneReviews, University of Washington; 1993-2021. [Last update: Jun 2015; Accessed: Feb 2020]

Ma L, Chung WK. [The role of genetics in pulmonary arterial hypertension](#). *J Pathol*. 2017;241(2):273-280.

Ma L, Roman-Campos D, Austin ED, et al. [A novel channelopathy in pulmonary arterial hypertension](#). *N Engl J Med*. 2013;369(4):351-361.

Prins KW, Thenappan T. [World Health Organization group I pulmonary hypertension: epidemiology and pathophysiology](#). *Cardiol Clin*. 2016;34(3):363-374.

Scientific Leadership Council. [Genetic testing and counseling for idiopathic and familial pulmonary arterial hypertension \(PAH\)](#). Pulmonary Hypertension Association. [Last revised: Nov 2008; Accessed: Nov 2018]

## Related Information

### [Pulmonary Arterial Hypertension Panel, Sequencing and Deletion/Duplication](#)

ARUP Laboratories is a nonprofit enterprise of the University of Utah and its Department of Pathology. 500 Chipeta Way, Salt Lake City, UT 84108  
 (800) 522-2787 | (801) 583-2787 | aruplab.com | arupconsult.com  
 Content Review May 2022 | Last Update November 2022